摘要
酪氨酸激酶抑制剂和免疫靶向药物的应用已经明显改变了 BCR∷ABL1阳性急性B淋巴细胞白血病的治疗策略和临床结果.2022年,世界卫生组织(WHO)和国际共识分型(ICC)相继对该疾病的分型进行了更新.2023年,美国国立综合癌症网络(NCCN)也首次更新了该疾病的预后分层,其治疗后的微小残留病评估和IKZF1plus基因分型是最关键的预后因素.以上更新将对临床诊疗产生重大影响,本文聚焦于该疾病分型和预后评估的最新更新内容展开综述.
Abstract
The application of tyrosine kinase inhibitors and targeted immunotherapy has revolu-tionized the therapeutic strategies and clinical outcome for BCR∷ABL1-positive B-cell acute lymphoblas-tic leukemia(BCR∷ABL1+B-ALL).The classification was updated successively by the World Health Or-ganization and the International Consensus Classification in 2022.The risk stratification of this entity,for the first time,was modified by the National Comprehensive Cancer Network in 2023,both minimal residu-al disease assessment and IKZF1plus genotyping recognized as critical prognostic factors.These important updates would have significant implications for clinical management.Therefore,this review focused on the latest advances in the classification and prognostic evaluation of BCR∷ABL1+B-ALL.
万方数据